Related Experiment Video
Updated: Mar 24, 2026
Tissue Collection and RNA Extraction from the Human Osteoarthritic Knee Joint
Published on: July 22, 2021
Soluble biomarkers development in osteoarthritis: from discovery to personalized medicine
Yves Henrotin1,2,3,4, Christelle Sanchez1, Anne Cornet3
1a Bone and Cartilage Research Unit, Arthropôle Liège, University of Liège, Institute of Pathology , CHU Sart-Tilman , Liège , Belgium .
Context:
Specific soluble biomarkers could be a precious tool for diagnosis, prognosis and personalized management of osteoarthritic (OA) patients.
Objective:
To describe the path of soluble biomarker development from discovery to clinical qualification and regulatory adoption toward OA-related biomarker qualification.
Methods And Results:
This review summarizes current guidance on the use of biomarkers in OA in clinical trials and their utility at five stages, including preclinical development and phase 1 to phase 4 trials. It also presents all the available regulatory requirements.
Conclusions:
The path through the adoption of a specific soluble biomarker for OA is steep but is worth the challenge due to the benefit that it can provide.
